Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons

被引:0
作者
Chakrapani Balijepalli
Rohan Shirali
Prashanth Kandaswamy
Anastasia Ustyugova
Egon Pfarr
Søren S. Lund
Eric Druyts
机构
[1] Precision Health Economics,
[2] Boehringer Ingelheim GmbH,undefined
来源
Diabetes Therapy | 2018年 / 9卷
关键词
Cardiovascular outcomes; DPP-4 inhibitors; Empagliflozin; Network meta-analysis; Saxagliptin; Sitagliptin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1491 / 1500
页数:9
相关论文
共 147 条
[1]  
Huxley R(2006)Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies BMJ 332 73-78
[2]  
Barzi F(2008)The growing burden of diabetes mellitus in the US elderly population Arch Intern Med. 168 192-199
[3]  
Woodward M(2003)Epidemiology of cardiovascular complications in type 2 diabetes mellitus Acta Diabetol 40 S358-S361
[4]  
Sloan FA(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149
[5]  
Bethel MA(2009)Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 32 187-192
[6]  
Ruiz D(2015)Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials Lancet Diabetes Endocrinol. 3 356-366
[7]  
Shea AM(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[8]  
Feinglos MN(2015)Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 232-242
[9]  
Meigs JB(2015)Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2247-2257
[10]  
Inzucchi SE(2013)Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 1317-1326